Phase III Clinical Study of NPB-01 in Patients With Autoimmune

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04561557` - Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System	Early Phase 1
Completed	`NCT05645185` - Characterisation of Clinical Phenotypes and Outcomes of Ma2 Patient
Not yet recruiting	`NCT04106596` - HLA Analysis in Autoimmune Encephalitis and Related Disorders
Completed	`NCT04708626` - Epidemiology of Autoimmune Encephalitides and Paraneoplastic Neurological Syndromes in Sweden
Not yet recruiting	`NCT05711563` - Predicting and Monitoring Outcomes in Autoimmune Encephalitis
Completed	`NCT04175522` - Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis:	Phase 2
Recruiting	`NCT03194815` - IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2	Phase 2
Recruiting	`NCT06079294` - Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism	N/A
Not yet recruiting	`NCT03957616` - Incidence of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis
Completed	`NCT02905136` - Mechanisms of Auto-immune Encephalitis
Recruiting	`NCT05280600` - Developing Advanced Neuroimaging for Clinical Evaluation of Autoimmune Encephalitis
Recruiting	`NCT06173076` - A Prospective Study to Evaluate Clinical Outcomes in Anti-LGI1 Encephalitis
Recruiting	`NCT03993262` - Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis	Phase 2
Recruiting	`NCT06033846` - Efficacy and Safety of Adjunctive Minocycline in the Treatment of Autoimmune Encephalitis	Phase 2
Recruiting	`NCT04372615` - The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis	Phase 2
Active, not recruiting	`NCT06432803` - Metabolic Imaging for Diagnosis and Prognostication of Autoimmune encephalitiS
Recruiting	`NCT06019975` - FDG-PET in the Diagnosis of Autoimmune Encephalitis
Completed	`NCT05783947` - Diagnostic Performance of a Commercial Assay for the Detection of Neuronal Antibodies
Not yet recruiting	`NCT06456736` - Clinical Features and Prognostic Markers in Adult Patients With AE Requiring ICU Treatment
Completed	`NCT05825690` - BRIEF TITLE * (in English and Sufficiently Descriptive) Role of MRI in Anti-LGI1 Encephalitis

NCT number	NCT05177939
Study type	Interventional
Source	Nihon Pharmaceutical Co., Ltd
Contact	Mamoru Ota
Phone	03-5148-7574
Email	kaihatsu@nihon-pharm.co.jp
Status	Recruiting
Phase	Phase 3
Start date	March 3, 2022
Completion date	October 31, 2024

Phase III Clinical Study of NPB-01 in Patients With Autoimmune Encephalitis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms